The Long-Term Safety and Quality of Life Effects of Oats in Dermatitis Herpetiformis
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients and Study Design
2.2. Clinical and Dietary Information
2.3. Questionnaires
Validated Questionnaires
2.4. Statistics
3. Results
3.1. Baseline data of DH Patients on a Gluten-Free Diet with and without Oats
3.2. Follow-Up Data of DH Patients on a Gluten-Free Diet with or without Oats
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Kárpáti, S. Dermatitis Herpetiformis. Clin. Dermatol. 2012, 30, 56–59. [Google Scholar] [CrossRef] [PubMed]
- Mansikka, E.; Hervonen, K.; Salmi, T.T.; Kautiainen, H.; Kaukinen, K.; Collin, P.; Reunala, T. The Decreasing Prevalence of Severe Villous Atrophy in Dermatitis Herpetiformis: A 45-Year Experience in 393 Patients. J. Clin. Gastroenterol. 2017, 51, 235–239. [Google Scholar] [CrossRef] [PubMed]
- Alakoski, A.; Salmi, T.T.; Hervonen, K.; Kautiainen, H. Chronic Gastritis in Dermatitis Herpetiformis: A Controlled Study. Clin. Dev. Immunol. 2012, 2012. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Dieterich, W.; Laag, E.; Schöpper, H.; Volta, U. Autoantibodies to Tissue Transglutaminase as Predictors of Celiac Disease. Gastroenterology 1998, 115, 1317–1321. [Google Scholar] [CrossRef]
- Dieterich, W.; Schuppan, D.; Laag, E.; Bruckner-Tuderman, L. Antibodies to Tissue Transglutaminase as Serologic Markers in Patients with Dermatitis Herpetiformis. J. Investig. Dermatol. 1999, 113, 133–136. [Google Scholar] [CrossRef]
- Sárdy, M.; Kárpáti, S.; Merkl, B.; Paulsson, M. Epidermal Transglutaminase (TGase 3) Is the Autoantigen of Dermatitis Herpetiformis. J. Exp. Med. 2002, 195, 747–757. [Google Scholar] [CrossRef]
- Fry, L.; Seah, P.P.; Riches, D.J.; Hoffbrand, A.V. Clearance of Skin Lesions in Dermatitis Herpetiformis after Gluten Withdrawal. Lancet Lond. Engl. 1973, 1, 288. [Google Scholar] [CrossRef]
- Reunala, T.; Blomqvist, K.; Tarpila, S.; Halme, H.; Kangas, K. Gluten-Free Diet in Dermatitis Herpetiformis. I. Clinical Response of Skin Lesions in 81 Patients. Br. J. Dermatol. 1977, 97, 473. [Google Scholar] [CrossRef]
- Galli, G.; Esposito, G.; Lahner, E.; Pilozzi, E.; Corleto, V.D.; Di Giulio, E.; Aloe Spiriti, M.A.; Annibale, B. Histological Recovery and Gluten-free Diet Adherence: A Prospective 1-year Follow-up Study of Adult Patients with Coeliac Disease. Aliment. Pharmacol. Ther. 2014, 40, 639–647. [Google Scholar] [CrossRef]
- Ciacci, C.; Cirillo, M.; Cavallaro, R.; Mazzacca, G. Long-Term Follow-up of Celiac Adults on Gluten-Free Diet: Prevalence and Correlates of Intestinal Damage. Digestion 2002, 66, 178. [Google Scholar] [CrossRef]
- Reunala, T.; Salmi, T.T.; Hervonen, K.; Laurila, K.; Kautiainen, H.; Collin, P.; Kaukinen, K. IgA Antiepidermal Transglutaminase Antibodies in Dermatitis Herpetiformis: A Significant but Not Complete Response to a Gluten-free Diet Treatment. Br. J. Dermatol. 2015, 172, 1139–1141. [Google Scholar] [CrossRef] [PubMed]
- Dipper, C.R.; Maitra, S.; Thomas, R.; Lamb, C.A. Anti-Tissue Transglutaminase Antibodies in the Follow-up of Adult Coeliac Disease. Aliment. Pharmacol. Ther. 2009, 30, 236. [Google Scholar] [CrossRef] [PubMed]
- Lewis, H.M.; Renaula, T.L.; Garioch, J.J.; Leonard, J.N. Protective Effect of Gluten-Free Diet against Development of Lymphoma in Dermatitis Herpetiformis. Br. J. Dermatol. 1996, 135, 363. [Google Scholar] [CrossRef] [PubMed]
- Grainge, M.J.; West, J.; Solaymani-Dodaran, M.; Card, T.R. The Long-Term Risk of Malignancy Following a Diagnosis of Coeliac Disease or Dermatitis Herpetiformis: A Cohort Study. Aliment. Pharmacol. Ther. 2012, 35, 730. [Google Scholar] [CrossRef]
- Pinto-Sánchez, M.; Mohaidle, A.; Baistrocchi, A.; Matoso, D.; Vázquez, H.; González, A.; Mazure, R.; Maffei, E.; Ferrari, G.; Smecuol, E.; et al. Risk of Fracture in Celiac Disease: Gender, Dietary Compliance, or Both. World J. Gastroenterol. 2011, 17, 3035–3042. [Google Scholar] [CrossRef]
- Pasternack, C.; Kaukinen, K.; Kurppa, K.; Mäki, M.; Collin, P.; Reunala, T.; Huhtala, H.; Salmi, T. Quality of Life and Gastrointestinal Symptoms in Long-Term Treated Dermatitis Herpetiformis Patients: A Cross-Sectional Study in Finland. Am. J. Clin. Dermatol. 2015, 16, 545–552. [Google Scholar] [CrossRef]
- Wagner, G.; Berger, G.; Sinnreich, U.; Grylli, V. Quality of Life in Adolescents with Treated Coeliac Disease: Influence of Compliance and Age at Diagnosis. J. Pediatr. Gastroenterol. Nutr. 2008, 47, 555. [Google Scholar] [CrossRef]
- Lee, A.R.; Wolf, R.L.; Lebwohl, B.; Ciaccio, E.J. Persistent Economic Burden of the Gluten Free Diet. Nutrients 2019, 11, 399. [Google Scholar] [CrossRef]
- Wild, D.; Robins, G.G.; Burley, V.J.; Howdle, P.D. Evidence of High Sugar Intake, and Low Fibre and Mineral Intake, in the Gluten-free Diet. Aliment. Pharmacol. Ther. 2010, 32, 573–581. [Google Scholar] [CrossRef]
- Ciacci, C.; Ciclitira, P.; Hadjivassiliou, M.; Kaukinen, K.; Ludvigsson, J.; McGough, N.; Sanders, D.; Woodward, J.; Leonard, J.; Swift, G. The Gluten-Free Diet and Its Current Application in Coeliac Disease and Dermatitis Herpetiformis. United Eur. Gastroenterol. J. 2015, 3, 121. [Google Scholar] [CrossRef]
- Aaltonen, K.; Laurikka, P.; Huhtala, H.; Mäki, M.; Kaukinen, K.; Kurppa, K. The Long-Term Consumption of Oats in Celiac Disease Patients Is Safe: A Large Cross-Sectional Study. Nutrients 2017, 9, 611. [Google Scholar] [CrossRef] [PubMed]
- Kaukinen, K.; Collin, P.; Huhtala, H.; Mäki, M. Long-Term Consumption of Oats in Adult Celiac Disease Patients. Nutrients 2013, 5, 4380. [Google Scholar] [CrossRef] [PubMed]
- Janatuinen, E.K.; Pikkarainen, P.H.; Kemppainen, T.A.; Kosma, V.-M. A Comparison of Diets with and without Oats in Adults with Celiac Disease. N. Engl. J. Med. 1995, 333, 1033. [Google Scholar] [CrossRef] [PubMed]
- Janatuinen, E.K.; Kemppainen, T.A.; Julkunen, R.J.K.; Kosma, V.-M. No Harm from Five Year Ingestion of Oats in Coeliac Disease. Gut 2002, 50, 332. [Google Scholar] [CrossRef] [PubMed]
- Peräaho, M.; Kaukinen, K.; Mustalahti, K.; Vuolteenaho, N.; Mäki, M.; Laippala, P.; Collin, P. Effect of an Oats-Containing Gluten-Free Diet on Symptoms and Quality of Life in Coeliac Disease. A Randomized Study. Scand. J. Gastroenterol. 2004, 39, 27–31. [Google Scholar] [CrossRef]
- Lundin, K.E.A.; Nilsen, E.M.; Scott, H.G.; Løberg, E.M.; Gjøen, A.; Bratlie, J.; Skar, V.; Mendez, E.; Løvik, A.; Kett, K. Oats Induced Villous Atrophy in Coeliac Disease. Gut 2003, 52, 1649–1652. [Google Scholar] [CrossRef]
- Sjöberg, V.; Hollén, E.; Pietz, G.; Magnusson, K.-E.; Fälth-Magnusson, K.; Sundström, M.; Holmgren Peterson, K.; Sandström, O.; Hernell, O.; Hammarström, S.; et al. Noncontaminated Dietary Oats May Hamper Normalization of the Intestinal Immune Status in Childhood Celiac Disease. Clin. Transl. Gastroenterol. 2014, 5, e58. [Google Scholar] [CrossRef]
- Reunala, T.; Collin, P.; Holm, K.; Pikkarainen, P.; Miettinen, A.; Vuolteenaho, N.; Mäki, M. Tolerance to Oats in Dermatitis Herpetiformis. Gut 1998, 43, 490–493. [Google Scholar] [CrossRef]
- Hardman, C.M.; Garioch, J.J.; Leonard, J.N.; Thomas, H.J. Absence of Toxicity of Oats in Patients with Dermatitis Herpetiformis. N. Engl. J. Med. 1997, 337, 1884. [Google Scholar] [CrossRef]
- Smulders, M.J.M.; van de Wiel, C.C.M.; van den Broeck, H.C.; van der Meer, I.M.; Israel-Hoevelaken, T.P.M.; Timmer, R.D.; van Dinter, B.-J.; Braun, S.; Gilissen, L.J.W.J. Oats in Healthy Gluten-Free and Regular Diets: A Perspective. Food Res. Int. 2018, 110, 3–10. [Google Scholar] [CrossRef]
- Comino, I.; de Lourdes, M.M.; Sousa, C. Role of Oats in Celiac Disease. World J. Gastroenterol. 2015, 21, 11825–11831. [Google Scholar] [CrossRef] [PubMed]
- Peräaho, M.; Collin, P.; Kaukinen, K.; Kekkonen, L. Oats Can Diversify a Gluten-Free Diet in Celiac Disease and Dermatitis Herpetiformis. J. Am. Diet. Assoc. 2004, 104, 1148–1150. [Google Scholar] [CrossRef] [PubMed]
- Salmi, T.T.; Hervonen, K.; Kautiainen, H.; Collin, P. Prevalence and Incidence of Dermatitis Herpetiformis: A 40-year Prospective Study from Finland. Br. J. Dermatol. 2011, 165, 354–359. [Google Scholar] [CrossRef] [PubMed]
- Hervonen, K.; Alakoski, A.; Salmi, T.T.; Helakorpi, S.; Kautiainen, H.; Kaukinen, K.; Pukkala, E.; Collin, P.; Reunala, T. Reduced Mortality in Dermatitis Herpetiformis: A Population-based Study of 476 Patients. Br. J. Dermatol. 2012, 167, 1331–1337. [Google Scholar] [CrossRef]
- Mansikka, E.; Salmi, T.; Kaukinen, K.; Collin, P.; Huhtala, H.; Reunala, T.; Hervonen, K. Diagnostic Delay in Dermatitis Herpetiformis in a High-Prevalence Area. Acta Derm. Venereol. 2018, 98, 195–199. [Google Scholar] [CrossRef]
- Korponay-Szabó, I.R.; Halttunen, T.; Szalai, Z.; Laurila, K. In Vivo Targeting of Intestinal and Extraintestinal Transglutaminase 2 by Coeliac Autoantibodies. Gut 2004, 53, 641. [Google Scholar] [CrossRef]
- Svedlund, J.; Sjödin, I.; Dotevall, G. GSRS—A Clinical Rating Scale for Gastrointestinal Symptoms in Patients with Irritable Bowel Syndrome and Peptic Ulcer Disease. Dig. Dis. Sci. 1988, 33, 129. [Google Scholar] [CrossRef]
- Dimenäs, E.; Carlsson, G.; Glise, H.; Israelsson, B.; Wiklund, I. Relevance of Norm Values as Part of the Documentation of Quality of Life Instruments for Use in Upper Gastrointestinal Disease. Scand. J. Gastroenterol. Suppl. 1996, 221, 8. [Google Scholar] [CrossRef]
- Finlay, A.Y.; Khan, G.K. Dermatology Life Quality Index (DLQI)—A Simple Practical Measure for Routine Clinical Use. Clin. Exp. Dermatol. 1994, 19, 210. [Google Scholar] [CrossRef]
- Hallert, C.; Svensson, M.; Tholstrup, J.; Hultberg, B. Clinical Trial: B Vitamins Improve Health in Patients with Coeliac Disease Living on a Gluten-Free Diet. Aliment. Pharmacol. Ther. 2009, 29, 811. [Google Scholar] [CrossRef]
- Lewis, V.; Finlay, A.Y. 10 Years Experience of the Dermatology Life Quality Index (DLQI). J. Investig. Dermatol. Symp. Proc. 2004, 9, 169–180. [Google Scholar] [CrossRef] [PubMed]
- Pinto-Sánchez, M.; Causada-Calo, N.; Bercik, P.; Ford, A.C.; Murray, J.A.; Armstrong, D.; Semrad, C. Safety of Adding Oats to a Gluten-Free Diet for Patients with Celiac Disease: Systematic Review and Meta-Analysis of Clinical and Observational Studies. Gastroenterology 2017, 153, 395–409. [Google Scholar] [CrossRef] [PubMed]
- Reunala, T. Gluten-free diet in dermatitis herpetiformis. II. Morphological and immunological findings in the skin and small intestine of 12 patients and matched controls. Br. J. Dermatol. 1978, 98, 69–78. [Google Scholar] [CrossRef] [PubMed]
Oats, n = 256 (82%) | No Oats, n = 56 (18%) | p-Value | ||
---|---|---|---|---|
Females, n (%) | 125 (49) | 26 (46) | 0.745 | |
Age at diagnosis, median (Q1–Q3), years | 37 (27–50) | 39 (24–48) | 0.481 | |
Year of diagnosis (dg), median (Q1–Q3) | 1993 (1982–2002) | 1988 (1982–2000) | 0.184 | |
Dg < 1985, n (%) | 74 (29) | 18 (32) | ||
Dg 1985–1999, n (%) | 96 (38) | 24 (43) | ||
Dg 2000–2014, n (%) | 86 (34) | 14 (25) | ||
Duration of skin symptoms before diagnosis, median (Q1–Q3), months 1 | 11 (6–36) | 10 (5–60) | 0.671 | |
Severity of skin symptoms 2 at diagnosis, n (%)3 | 0.076 | |||
Mild | 26/167 (16) | 6/31 (19) | ||
Moderate | 90/167 (54) | 10/31 (32) | ||
Severe | 51/167 (31) | 15/31 (48) | ||
Gastrointestinal symptoms at diagnosis, n (%) | 108/227 (48) | 25/50 (50) | 0.756 | |
Small bowel histology at diagnosis, n (%) | 0.530 | |||
Normal | 43/207 (21) | 5/36 (14) | ||
Partial villous atrophy | 78/207 (37) | 13/36 (36) | ||
Subtotal/total villous atrophy | 86/207 (42) | 18/36 (50) | ||
Positive coeliac serology 3 at diagnosis, n (%) | 121/164 (74) | 19/31 (61) | 0.156 |
Oats, n = 256 (82%) | No Oats, n = 56 (18%) | p-Value | |
---|---|---|---|
Age, median (range), years | 62 (18–96) | 62 (32–85) | 0.963 |
Duration of GFD, median (range), years | 21 (1–47) | 24 (2–41) | 0.161 |
GFD adherence | 0.229 | ||
Strict, no dietary lapses, n (%) | 200/254 (79) | 49/56 (88) | |
Dietary lapses less than once a month, n (%) | 36/254 (14) | 6/56 (11) | |
Dietary lapses once a month or more often, n (%) | 18/254 (7) | 1/56 (2) | |
Skin symptoms, n (%)1 | 30/188 (16) | 10/36 (28) | 0.090 |
Dapsone treatment, n (%)1 | 8/188 (4) | 5/36 (14) | 0.040 |
Gastrointestinal symptoms, n (%)1 | 8/188 (4) | 7/36 (19) | 0.004 |
The total number of long-term illnesses, median (range)1 | 1 (0–12) | 1 (0–9) | 0.850 |
Coronary heart disease, n (%) | 20 (8) | 2 (4) | 0.261 |
Cerebrovascular disease, n (%) | 7 (3) | 1 (2) | 1.000 |
Osteoporosis or osteopenia, n (%) | 15 (6) | 3 (6) | 1.000 |
Bone fractures, n (%) | 49 (19) | 12 (21) | 0.696 |
Malignancy, n (%) | 22 (9) | 2 (4) | 0.273 |
Number of prescription medications used, median (range) 1 | 2 (0–4) | 2 (0–9) | 0.510 |
Number of over-the-counter medications used, median (range) 1 | 1 (0–5) | 1 (0–5) | 0.769 |
Current smoking, n (%)1 | 18 (7) | 9 (16) | 0.032 |
Body mass index, kg/m2, median (range)1 | 25 (17–40) | 26 (20–33) | 0.242 |
Oats, n = 256 (82%) | No Oats, n = 56 (18%) | p-Value | ||
---|---|---|---|---|
median (Q1–Q3) | median (Q1–Q3) | |||
GSRS scores 1 | ||||
Total score | 1.7 (1.3–2.2) | 1.7 (1.4–2.2) | 0.322 | |
Abdominal pain | 1.7 (1.0–2.0) | 1.7 (1.0–2.0) | 0.722 | |
Reflux | 1.0 (1.0–2.0) | 1.0 (1.0–2.0) | 0.483 | |
Diarrhoea | 1.3 (1.0–2.0) | 1.3 (1.0–2.7) | 0.045 | |
Indigestion | 2.0 (1.5–2.8) | 2.0 (1.5–2.5) | 0.931 | |
Constipation | 1.3 (1.0–2.3) | 1.7 (1.0–2.3) | 0.570 | |
PGWB scores 2 | ||||
Total score | 110 (99–117) | 103 (94–118) | 0.083 | |
Anxiety | 26 (23–27) | 25 (22–27) | 0.364 | |
Depressed mood | 17 (16–18) | 17 (15–18) | 0.181 | |
Positive well-being | 18 (16–20) | 17 (15–20) | 0.266 | |
Self-control | 16 (15–17) | 15 (14–17) | 0.145 | |
General health | 14 (12–16) | 13 (11–15) | 0.020 | |
Vitality | 19 (17–21) | 18 (15–20) | 0.025 | |
DLQI score 3, 4 | 0 (0–0) | 0 (0–1) | 0.028 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Alakoski, A.; Hervonen, K.; Mansikka, E.; Reunala, T.; Kaukinen, K.; Kivelä, L.; Laurikka, P.; Huhtala, H.; Kurppa, K.; Salmi, T. The Long-Term Safety and Quality of Life Effects of Oats in Dermatitis Herpetiformis. Nutrients 2020, 12, 1060. https://doi.org/10.3390/nu12041060
Alakoski A, Hervonen K, Mansikka E, Reunala T, Kaukinen K, Kivelä L, Laurikka P, Huhtala H, Kurppa K, Salmi T. The Long-Term Safety and Quality of Life Effects of Oats in Dermatitis Herpetiformis. Nutrients. 2020; 12(4):1060. https://doi.org/10.3390/nu12041060
Chicago/Turabian StyleAlakoski, Anna, Kaisa Hervonen, Eriika Mansikka, Timo Reunala, Katri Kaukinen, Laura Kivelä, Pilvi Laurikka, Heini Huhtala, Kalle Kurppa, and Teea Salmi. 2020. "The Long-Term Safety and Quality of Life Effects of Oats in Dermatitis Herpetiformis" Nutrients 12, no. 4: 1060. https://doi.org/10.3390/nu12041060
APA StyleAlakoski, A., Hervonen, K., Mansikka, E., Reunala, T., Kaukinen, K., Kivelä, L., Laurikka, P., Huhtala, H., Kurppa, K., & Salmi, T. (2020). The Long-Term Safety and Quality of Life Effects of Oats in Dermatitis Herpetiformis. Nutrients, 12(4), 1060. https://doi.org/10.3390/nu12041060